Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
52.94
-0.01 (-0.02%)
At close: Apr 28, 2026, 4:00 PM EDT
52.86
-0.08 (-0.15%)
After-hours: Apr 28, 2026, 6:06 PM EDT
Terns Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | - | - | 1 | |
| Gross Profit | - | - | - | - | 1 | |
| Selling, General & Admin | 32.24 | 31.76 | 39.06 | 22.41 | 19.55 | |
| Research & Development | 77.89 | 70.11 | 63.5 | 39.62 | 31.31 | |
| Operating Expenses | 110.12 | 101.87 | 102.56 | 62.03 | 50.86 | |
| Operating Income | -110.12 | -101.87 | -102.56 | -62.03 | -49.86 | |
| Interest & Investment Income | 14.59 | 13.29 | 12.9 | 2.11 | 0.17 | |
| Other Non Operating Income (Expenses) | -0.09 | -0.01 | -0.31 | -0.07 | 0.04 | |
| EBT Excluding Unusual Items | -95.63 | -88.59 | -89.97 | -59.99 | -49.65 | |
| Pretax Income | -95.63 | -88.59 | -89.97 | -59.99 | -49.65 | |
| Income Tax Expense | 0.58 | 0.26 | 0.24 | 0.36 | 0.51 | |
| Earnings From Continuing Operations | -96.21 | -88.85 | -90.21 | -60.35 | -50.16 | |
| Net Income | -96.21 | -88.85 | -90.21 | -60.35 | -50.16 | |
| Net Income to Common | -96.21 | -88.85 | -90.21 | -60.35 | -50.16 | |
| Shares Outstanding (Basic) | 93 | 80 | 71 | 36 | 23 | |
| Shares Outstanding (Diluted) | 93 | 80 | 71 | 36 | 23 | |
| Shares Change (YoY) | 17.18% | 11.58% | 97.76% | 58.69% | 7862.47% | |
| EPS (Basic) | -1.03 | -1.12 | -1.27 | -1.67 | -2.21 | |
| EPS (Diluted) | -1.03 | -1.12 | -1.27 | -1.67 | -2.21 | |
| Free Cash Flow | -82.18 | -70.06 | -67.44 | -49.38 | -42.17 | |
| Free Cash Flow Per Share | -0.88 | -0.88 | -0.95 | -1.37 | -1.86 | |
| Gross Margin | - | - | - | - | 100.00% | |
| Operating Margin | - | - | - | - | -4986.00% | |
| Profit Margin | - | - | - | - | -5015.80% | |
| Free Cash Flow Margin | - | - | - | - | -4216.70% | |
| EBITDA | -110.03 | -101.55 | -102.27 | -61.55 | -49.35 | |
| D&A For EBITDA | 0.09 | 0.32 | 0.29 | 0.48 | 0.51 | |
| EBIT | -110.12 | -101.87 | -102.56 | -62.03 | -49.86 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.